Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles. Read More
(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses. Read More
Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona. Read More
(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes. Read More
(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies. Read More
Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024. Read More
(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment. Read More
Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease. Read More
(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline". Read More
Syncona Ltd - London-based investor in healthcare companies - Says portfolio company Achilles Therapeutics reports that pretax loss widened to USD16.7 million in the third quarter of 2023 from USD12.4 million the year before, as operating expenses rose 19% to USD19.1 million from USD16.0 million a year ago. Achilles is a Philadelphia, US-based clinical-stage biopharmaceutical company which develops novel cancer immunotherapies. Syncona owns a 25% stake in Achilles. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News: Read More
Syncona Ltd - London-based investor in healthcare companies - Says Syncona Investment Management Ltd has submitted a non-binding proposal to acquire the entire remaining share capital of Freeline Therapeutic Holdings PLC. Offers upfront cash consideration of USD5.00 per American depository share, representing a 20% premium over the USD4.16 volume weighted average price from October 4 to October 16. Syncona currently owns around 57.9% of shares in Stevenage, England-based Freeline, which it co-founded in 2015. Freeline aims to develop gene therapies to treat chronic diseases, most notably its potentially "transformative" FLT201 programme to treat Gaucher disease. Read More
(Alliance News) - Syncona Ltd on Wednesday said its portfolio company Freeline Therapeutics Holdings PLC has received positive initial safety, tolerability and enzyme activity data from its FLT201 trial for the treatment of Gaucher disease. Read More
Syncona Ltd - London-based investor in healthcare companies - Launches share buyback programme worth up to GBP40.0 million, to be conducted by Numis Securities Ltd. Says core focus remains on allocating capital to portfolio companies' assets. However the buyback is necessary due to Syncona's shares currently trading at a discount to net asset value, which was 184.6 pence per share at June 30. Says buyback will not affect investments into clinical stage assets planned for the next 24 months. Company expects that capital deployment into portfolio and pipeline will total between GBP150 million and GBP200 million for the year ending March 31, in line with prior guidance. Chair Melanie Gee says Syncona "has a high level of confidence in our portfolio and its valuation". Read More
(Alliance News) - Syncona Ltd on Monday said it has been informed by Swiss-American pharmaceutical company Novartis AG that the development of eye treatment, GT005, for geographic atrophy secondary to dry age-related macular degeneration will be discontinued. Read More
(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data. Read More
Syncona Ltd - London-based healthcare investor - Notes second quarter results announcement from its Nasdaq-listed portfolio company Freeline Therapeutics Holdings PLC. Says the key highlights include Freeline completing the dosing in the first dose cohort of the phase 1/2 trial of FLT201 in Gaucher disease, following dosing of the second patient. Says initial clinical data from the FLT201 trial is expected in the second half of 2023. Also says Freeline has a cash position of USD38.8 million at June 30 compared to USD55.4 million on March 31, which Freeline expects will enable the company to fund its planned operations into the second quarter of 2024. Freeline says net income in the three months that ended June 30 narrowed to USD14.8 million from USD51.1 million a year earlier. Read More